What's Happening?
Bruin Biometrics Inc., a UCLA spin-off, has developed a scanning device called ProVizio to detect precursor conditions for pressure ulcers, a significant issue in healthcare costing up to $27 billion annually. The device, which has received FDA clearance,
allows caregivers to identify potential pressure ulcers before they form, enabling early intervention. This technology is particularly crucial as pressure ulcers affect millions annually, with treatment costs reaching up to $70,000 per case. The device is primarily used in hospitals, skilled nursing facilities, and home-care settings, providing a proactive approach to managing pressure injuries.
Why It's Important?
The introduction of the ProVizio device represents a significant advancement in preventing pressure ulcers, which are a major healthcare burden. By enabling early detection, the device can reduce treatment costs and improve patient outcomes. This innovation addresses a critical need in healthcare, potentially saving billions in treatment expenses and reducing the incidence of hospital-acquired pressure ulcers. The device's success could lead to broader adoption of similar technologies, transforming care practices for non-ambulatory patients.
What's Next?
Bruin Biometrics plans to seek FDA clearance for expanded use of the ProVizio device on patients with diabetes and circulatory problems. The company is also working to increase market penetration for the device's approved uses. Efforts to secure reimbursement from Medicare and Medicaid for the device's use are ongoing, which could further drive adoption in healthcare facilities. The company aims to demonstrate the cost-saving benefits of the device to healthcare providers, potentially leading to widespread implementation.
